REVIEW ARTICLES

Infecţia acută cu CMV în timpul sarcinii

 Acute CMV infection in pregnancy

First published: 23 decembrie 2020

Editorial Group: MEDICHUB MEDIA

DOI: 10.26416/ObsGin.68.4.2020.4021

Abstract

Primary cytomegalovirus (CMV) infection is still a major problem in developing countries despite screening programs. Due to nonspecific symptoms and reduced therapeutic possibilities, the morbidity of this infection may be increased. The confirmation of this infection in the first part of pregnancy requires careful imaging surveillance and, possibly, a confirmation of fetal impairment using invasive methods. Even in the context of normal fetal imaging, the postnatal impairment cannot be completely ruled out, therefore the follow-up of these children in the first years of life is mandatory.

Keywords
CMV, cCMV, neurological impairment, MRI

Rezumat

Infecţia primară cu citomegalovirus (CMV) este încă o problemă importantă în ţările în curs de dezvoltare, în ciuda programelor de screening. Din cauza simptomelor nespecifice şi a posibilităţilor terapeutice reduse, morbiditatea acestei infecţii poate fi crescută. Confirmarea infecţiei în prima parte a sarcinii impune o supraveghere imagistică atentă şi, eventual, o confirmare a afectării fetale prin metode invazive. Chiar şi în contextul unei imagistici fetale normale, afectarea postnatală nu poate fi complet exclusă, motiv pentru care supravegherea acestor copii în primii ani de viaţă este obligatorie.

Introduction

Cytomegalovirus (CMV) is a member of the Herpesviridae family, which belongs to DNA viruses, and is common in the general population(1). The rates of seropositivity in adult women are ranging from 40% (in most European countries) to 90% (in African and Asian countries)(2,3).

Congenital cytomegalovirus infection (cCMV) is the most common non-genetic cause of sensorineural hearing loss (SNHL), accounting for 25-30% of cases of childhood sensorineural deafness(4), and one of the congenital infections that cause significant neurological impairment in children from USA and Northern Europe(5).

Several factors contribute decisively to the underdiagnosis of CMV in childhood, which leads to an increased rate of morbidity and mortality in these infants. These include limited awareness of the CMV infectious risk in both parents and doctors(6,7), lack of recognition of the infection (due to nonspecific symptoms in both pregnant women and newborns), lack of screening programs in some countries, and low effective vaccines and treatment regimens(8).

Epidemiology

Primary CMV infection occurs as a result of close personal contact and is transmitted through fluids, body secretions or vertically (transplacental), leading to congenital infection in the fetus(3).

CMV infection is the most common intrauterine infection, affecting 0.3-2% of live births(9), being defined as active CMV infection when detected in the first three weeks of life(10).

The overall prevalence of cCMV has been estimated around 0.7%, but it varies widely worldwide, being estimated between 0.48% and 1.3% in the United States(10), 0.54% in The Netherlands(11), and 1.08% in Brazil(12).

In the past, symptomatic cCMV infection was considered to occur only after the mother’s primary infection during pregnancy, and preexisting maternal immunity prevented the fetus from being at risk for infection in recurrent maternal infection(3). These assumptions led to the conclusion that populations with high rates of seroprevalence may have a lower risk of primary ma­ter­nal CMV infection and therefore lower risks of cCMV, which is not entirely true(3). This assumption was ques­tioned because it was observed that populations with low socioeconomic status and high seropositivity rates in women of reproductive age usually have higher overall rates of cCMV infection (1-2%), compared to the global average (0.4-0.7%)(3).

These observations led to the hypothesis of secondary CMV infections in pregnant women immunized for CMV at conception (either by reactivation of the latent virus or reinfection with a new CMV strain). These infections can also lead to cCMV and fetal infection(13), but with a lower risk rate, around 1.4%(14).

Furthermore, some authors hypothesized that reinfec­tion with a new strain of CMV can lead to a higher risk of cCMV compared with the viral reactivation, but this has not been clearly established(15).

The incidence of primary CMV infection in pregnant women varies between 0.5% and 4%(1), but only about one third (30-39%) of these infections will result in trans­mit­ting the virus to the fetus(3). The risk of fetal CMV in­fec­tion is higher with primary maternal infection and less likely with recurrent infection(3).

Also, the severe forms of disease occur more commonly among fetuses whose mothers suffer from a primary infection in the first half of pregnancy, although the viral transmission rate is 8.3%(16), up to 8.8%(17) in the first 18 weeks of pregnancy, compared to the third trimester, when CMV transmission varies between 40% and 70%, but when newborns are more commonly asymptomatic(17,18).

For these reasons, the Society of Maternal-Fetal Medicine recommends explaining to the pregnant women with primary CMV infection that the risk of congenital infection varies, on average, between 30% and 50%, but the severity of the disease cannot be anticipated(19).

What is certain is that determining the timing of CMV infection is important in order to determine the risk of fetal infection(19), the primary infection having a 20-fold higher risk of vertical transmission compared to CMV reactivation or reinfection (30% versus 1.4%)(3).

Maternal diagnosis of CMV infection

1. Clinical

In pregnant women, CMV infection is asymptomatic or usually appears with mild clinical symptoms, and there­fore this condition is difficult to recognize if the sero­logy testing on CMV is not done as a routine screening in the first trimester of pregnancy(1). For these reasons, the CMV infection can be easily overlooked, leading to fetal infection and to congenital CMV(1).

Most studies have shown that less than 5% of pregnant women with primary CMV infection have flu-like syndrome, defined by simultaneous occurrence of fever, pharyngitis, cervical lymphadenopathy, fatigue, malaise, myalgia, headache, hepatosplenomegaly or rash(20,21).

2. Laboratory

Changes in laboratory tests, such as lymphocytosis and increased transaminases, may indicate the presence of CMV infection in 12% to 36% of pregnant women affected by this condition, but these are nonspecific and may be caused by other viral infections(22).

3. Serology

Infectious serological screening is essential for the early detection of CMV infection, but in some countries, such as Australia, New Zealand or USA(3), it is no longer performed, while in other countries (Austria, Belgium, France, Germany, Israel, Italy, Portugal, Spain and The Netherlands) it is carried out only for certain risk groups(23).

However, in Romania, the screening is mandatory in the first trimester of pregnancy, being added to the TORCH profile, along with hepatitis B, C, VDRL and syphilis.

Usually, the presence of IgM antibody indicates an acute infection, but this antibody can be produced during secondary infections, or may be false positive in response to other viral infections, such as Epstein-Barr virus, herpes simplex virus (HSV) or varicella-zoster virus (VZV)(19,24). IgM can also persist for several months following the pri­mary infection, potentially predating pregnancy by a sig­ni­ficant period of time(19). Therefore, the presence of IgM alone should not be used for diagnosis(19).

The diagnosis of primary CMV infection is made by documenting seroconversion and the appearance of virus-specific IgG antibodies in the pregnant woman serum, previously known as seronegative. The presence of IgG antibodies indicates a past infection, but the time interval from this infection, especially if IgM are also positive, varies from two weeks to one year(25). Approxi­mately 1-4% of the seronegative women will have a pri­mary infection during pregnancy, and the majority of these women will be asymptomatic(19).

If the IgM CMV antibodies are detected without specific IgG CMV antibodies, the primary infections diagnosis is clear(26). Unfortunately, this clinical situations is rare, because of the rapid increase of IgG antibodies after the acute infection and due to a decreased of CMV screening in many countries(26).

For this reasons, in countries without CMV screening programs or when we have both the IgM CMV and IgG CMV present, the IgG CMV avidity test is considered essential to establish the infection time or to differentiate a primary infection from the secondary one(3,27,28).

The IgG antibodies produced as a response for the primary CMV infections usually have low avidity, evolving in time for a better bond with the CMV antigens(27,28).

The avidity levels are mentioned as an avidity index, described as the IgG percent bonded to the antigens as a result of the agents distortion treatment, and can be a sensitive marker for a primary CMV infection in the last 4 months(19).

For these reasons, the Society of Perinatal Medicine recom­mends that for women suspected of primary CMV infection during pregnancy, the diagnose should be made using IgG seroconversion, or by IgM CMV +, IgG CMV + and low IgG avidity(19).

4. Polymerase chain reaction (PCR) testing is a fast and sensitive method in detecting CMV, which has become widely available in recent years and has as its mechanism the amplification of nucleic acids. This technique examines either the well preserved genetic antigens fragments, or some specific DNA fragments – showing a high sensibility in pathogen agent detection(29).

Molecular methods can be used for CMV nucleic acids detections, as well as for viral replication diagnosis from specific cells culture(24).

The CMV may be isolated from several biological samples, including blood, urine, saliva, semen, vaginal discharge and amniotic fluid(24). Viremia may persist for up to one month after the primary infection, but detectable viremia has also been reported in seropositive women with recurrent infections usually at lower values(30,31).

PCR identification of CMV DNA can be qualitative or quantitative. Quantitative PCR (real-time PCR) allows both the diagnosis and the treatment surveillance in the severe forms of the disease, but a threshold above which the risk of vertical transmission is higher could not be established(32,33).

The prenatal diagnosis of CMV infection

Only 10-20% of the fetuses exposed to CMV in utero will show signs of infection at birth, such as: intrauterine growth restriction, microcephaly, hepatosplenomegaly, thrombocytopenia, parenchymal calcifications of the brain, ventriculomegaly, cerebellar hypoplasia(34). Furthermore, neurodevelopmental sequelae such as mental retardation and motor/auditory or visual impairment may occur later in life, even in asymptomatic newborns(34).

In case of a primary maternal CMV infection, but without a confirmed fetal infection, the risk of severe fetal sequelae is approximately 3% and the overall risk of fetal impairment is around 8%(19).

The methods used for assessing primary infection are invasive (amniocentesis, cordocentesis) and noninvasive (imaging techniques), the disadvantage of the latter being that some changes may not be visible in the early stages of the infection and also that it cannot assess the severity of the lesions, especially the neurological lesions(35).

1. Invasive prenatal diagnostic techniques: amniocentesis or cordocentesis

The most common method used for prenatal diagnosis of CMV fetal infection is amniocentesis(36,37). The cordocentesis may be performed, having a sensitivity and specificity similar to those of amniotic fluid CMV testing, but with a higher complications rate compared to amniocentesis(36,37), which is why the usefulness in cCMV prenatal diagnosis is disputed(24).

The prenatal diagnosis of cCMV can be made either by viral cell culture or by detecting CMV DNA in an amniotic fluid sample using PCT or real time PCR(24). The molecular diagnosis by PCR is currently preferred to CMV culture, due to a higher sensitivity (90% to 100%)(5).

Although the amniotic fluid CMV-PCR is a test with increased sensitivity and specificity, it depends on when the amniocentesis is performed(22,24). The amniotic fluid taken before 21-22 weeks of pregnancy or less than 6 weeks after the primary maternal infection may have an undetectable CMV load due to the time required for CMV to be excreted by the fetal kidney, which is the primary site of viral shedding(22,24).

As a result, the Maternal-Fetal Medicine Association recommends carrying out amniocentesis for CMV detection after 21 weeks in pregnancy or more than 6 weeks since the primary maternal infection(19).

The use of real-time PCR allows a quantitative determination of the viral load, but currently there are differences of opinion regarding its value due to an increased risk of fetal complications. Some authors claim that a CMV viral load of more than 103 copies/ml in amniotic fluid correlates with fetal infection, and that viral loads higher than 105 copies/ml are associated with more severe forms of the disease(38). Other groups of investigators claim that a viral load in the amniotic fluid of more than 105 copies/ml was associated with symptomatic infection in the newborn or fetus(38,39), while others failed to establish a clear link between the viral load and the degree of fetal/neonatal impairment(40,41).

For this reasons, the professional forums recommend caution in assessing the degree of fetal impairment only on the basis of the CMV viral load from the amniotic fluid(5).

2. The imagistic/imaging investigations

The imagistic studies in cCMV have two main objectives: detecting the fetal structural abnormalities for confirming the fetal impairment, and providing in­for­mation on fetal prognosis(42).

However, certain sequelae of cCMV, such as chorioretinitis, petechiae and neurodevelopmental disorders, are not detectable by prenatal imaging methods, so the absence of imaging abnormalities does not rule out fetal impairment(43).

At a cellular level, CMV is able to affect multiple cell lines, nonetheless his action is targeted on the fetal brain and kidney(2,44,45). In neurons, astrocytes, glial cells and endothelial cells, CMV causes a number of changes in the neuronal proliferation and migration, as well as in the organization of cortical cells(44,45).

While ultrasound is the method of choice for fetal imaging, being easy and more accessible, MRI can bring additional information especially in the detection of fetal brain abnormalities, both structural and functional (metabolic)(46).

Ultrasound examination

Fetal structural changes identifiable through prenatal ultrasounds are: cerebral abnormalities, such as ventriculomegaly, brain calcifications, microcephaly, occipital horn variations, and non-cerebral abnormalities, such as echogenic bowel, intrauterine growth restriction, hepatosplenomegaly, ascites and cardiomegaly(35,47), growth in placental width (enlarged placenta – due to placental inflammation)(48), oligohydramnios and, seldom, polyhydramnios(2). Rare lesions, such as sub­ependymal cysts or intrahepatic calcifications, have also been reported, but these changes need to be confirmed by other studies(47).

The neurological ultrasound examination in the cCMV-confirmed cases is essential, because the cranial abnormalities like ventriculomegaly and microcephaly are associated with a poor neurocognitive prognosis(49).

The intracranial calcifications are a classic sign found in cCMV, usually described by ultrasound, being observed in the basal ganglia, as a manifestation of lenticular vasculopathy, but also in the cerebral parenchyma(50). Furthermore, according to Doneda et al., the suspicion of cCMV should be raised when these intracranial calcifications are detected in the anterior temporal lobe, also called “polar temporal lesion”(51).

The hyperechoic intestine is a classic ultrasound sign of cCMV, although it is sometimes overestimated(52), being caused either by direct injury of the virus to the intestine, or by intraamniotic hemorrhage(53).

cCMV is associated with an increased risk of fetal death in utero, even in the absence of suspicious ultrasound changes(43).

Magnetic Resonance Imaging (MRI)

Fetal MRI can be used especially in the detection of neurological abnormalities, particularly if the ultrasound has detected abnormalities at this level(54).

Fetal MRI is complementary and often superior to ultrasound in detecting abnormal gyration and myelination(51,55).

The timing to perform fetal MRI in cCMV is not well established, being preferred at the beginning of the third trimester (27-33 weeks of gestation), because some lesions, such as neuronal migration, are more difficult to detect in the first two trimesters(50,54).

The lesions identified by MRI in cCMV are often nonspecific, the most common abnormalities observed being ventriculomegaly and white matter (WM) signal abnormalities or cerebellar hypoplasia(42,56). Other brain lesions that can be seen on MRI are cerebral cysts, dilation of the temporal horns, ventriculitis and intracranial calcifications(50,51).

Congenital CMV infection affects the germinal matrix, leading to the loss of neurons and their disruption of migration when the infection occurs before 16-18 weeks of gestation(2,50). Lissencephaly and polymicrogyria can be seen in infections that occur between 18 and 24 weeks, while fetuses exposed to CMV in the third trimester usually have a normal gyral pattern(2,50).

Polimicrogyria occurs mainly in the frontal and perisilvic regions, due to a neural migratory disorder(57).

Hoffman et al.(58) found, using MRI examination, that the volume of the brain is smaller in fetuses with cCMV, an observation also confirmed by Grinberg et al.(9) One possible explanation of these MRI modifications could be the loss of neuronal stem cells, the disruption of migration and the differentiation of brain stem cells, as well as accentuated local inflammation and hypoxia(44).

Furthermore, Grinberg et al. found on MRI examination that there is a correlation between low cerebellar volume and neurobehavioral disorders in childhood, especially for daily activities and communication skills(9). There is an association between cerebellar lesions and the presence of some cognitive disorders, such as speech, behavioral, social and motor deficiencies(9,59).

Cerebellar abnormalities are a common feature in postnatal MRI for cCMV(60), but are less common in fetal MRI, either due to the fact that they occur later in pregnancy, or to the fact that children with symptomatic cCMV undergo more detailed imaging examinations(51,61).

Cerebellar hypoplasia and dysplasia can affect the vermis, cerebellar hemispheres, or both, and are associated with a high risk of childhood sequelae(2,51).

Other abnormalities of cCMV identifiable on MRI are: hepatomegaly, splenomegaly, intrauterine growth restriction (FGR), hyperechoic bowel, cutaneous edema, ascites, pleural and pericardial effusion, hydrops, oligo-/polyhydramnios and placentomegaly(48,62).

The isolated cases of hyperechoic bowel detected on ultrasound without other organic lesions are associated with normal MRI and a good prognosis(43).

In situations where both MRI and ultrasound are normal, the fetal prognosis is good and the rate of major complications in childhood is low(63).

However, normal brain imaging does not completely rule out the presence of neurodevelopmental disorders in childhood, especially since hearing loss is frequently progressive in cCMV.

The postnatal diagnosis of CMV infection

Congenital cytomegalovirus infection is the most common non-genetic cause of sensorineural hearing loss, accounting for 25-30% of cases of childhood sensorineural deafness(4).

Between 5% and 10% of the newborns with congenital cytomegalovirus infection are symptomatic, mainly the central nervous system being affected(64). On the other hand, the majority of the asymptomatic infants remain unidentified due to the lack of clinical manifestations(5).

The most common symptoms in the cCMV infection are jaundice, petechiae, hepatosplenomegaly and neurological anomalies, such as microcephaly and intracranial calcifications, which are found in up to 75% of cases(3,65). Less frequent signs that can also be observed are cataract, microphthalmia, myocarditis and cardiac defects(3,65).

Hepatobiliary abnormalities, confirmed by increased transaminases and conjugated hyperbilirubinemia, can be seen in 23-80% of symptomatic newborns, but they are only transient, with normalization in a few weeks(3,65).

The congenital CMV infection diagnostic can be confirmed by identifying the virus or the viral antigens in the newborns’ urine or saliva in the first two weeks of life(5). The presence of the virus or viral antigens after three weeks alone cannot confirm cCMV, because after this interval the CMV infection can be one acquired at birth or postnatal(5).

The serological methods are not very accurate for the postnatal confirmation of the diagnosis of cCMV, because the detection of CMV-IgG antibodies in fetal blood may be due to transplacental transfer of maternal antibodies, and the detection of CMV-IgM antibodies do not have a high level of sensitivity and specificity(66)

Treatment

The effectiveness of antiviral treatment during pregnancy is still a hot topic, due to the questionable efficacy and potential teratogenic risk of drugs. The clinical benefits of CMV-specific hyperimmune globulin treatment are also disputed, due to the discordant results obtained from various studies(16,67).

The treatment options for cCMV infections are still limited, because most drugs act by inhibiting CMV viral replication, but cannot remove the virus from the human body. It has also been observed that, after stopping antiviral therapy, the viral load in the blood tends to increase(68).

Studies have shown that a six-week course of ganciclovir, started in the neonatal period, is effective in reducing the severity of neurological sequelae and hearing loss in both symptomatic and asymptomatic infants(69,70), but unfortunately there is no benefit of a long-term use(68).

Regarding the antenatal use of CMV hyperimmune globulin (CMV HIG) to prevent infection in newborns, in a study published in 2014, the authors found no benefit of treatment, but there were a number of side effects in those who received CMV HIG(67).

The American College of Obstetricians and Gynecologists (ACOG) does not currently recommend the prenatal treatment with ganciclovir or valaciclovir because it has not been shown to be effective(71). These observations are also reinforced by the Society of Maternal-Fetal Medi­cine, which does not recommend the prenatal treatment with ganciclovir or valaciclovir or the antenatal therapy, either with antivirals or with CMV HIG(19).

Conclusions

CMV remains the leading infectious cause of birth defects in both the fetus and the newborn.

An increasing number of evidence indicates that the CMV reinfection during pregnancy contributes to a much larger proportion of symptomatic cCMV than was previously supposed.

For this reason, avoiding exposure of pregnant women to CMV or serological screening should be recommended for both seronegative and seropositive pregnant women.

In cases of confirmed or suspected primary maternal CMV infection, amniotic fluid viremia obtained by amniocentesis, as well as prenatal ultrasound and, possibly, MRI evaluation are required to determine the risk of cCMV and to assess the possible fetal damage.

MRI can bring additional information especially in the case of brain abnormalities and can achieve a better assessment of the neonatal prognosis. 

Bibliografie

  • 1. Porobic-Jahic H, Skokic F, Ahmetagic S, Piljic D, Jahic R, Petrovic J. Cytomegalovirus Infection in Pregnancy – Our Experiences. Med Arch (Sarajevo, Bosnia Herzegovina). 2019 June;73(3):149-53. 

  • 2. Leruez-Ville M, Ville Y. Fetal cytomegalovirus infection. Best Pract Res Clin Obstet Gynaecol. 2017 Jan;38:97-107. 

  • 3. Naing ZW, Scott GM, Shand A, Hamilton ST, van Zuylen WJ, Basha J, et al. Congenital cytomegalovirus infection in pregnancy: a review of prevalence, clinical features, diagnosis and prevention. Aust NZJ Obstet Gynaecol. 2016 Feb;56(1):9-18. 

  • 4. Morton CC, Nance WE. Newborn hearing screening – a silent revolution. N Engl J Med. 2006 May;354(20):2151-64. 

  • 5. Ross SA, Novak Z, Pati S, Boppana SB. Overview of the diagnosis of cytomegalovirus infection. Infect Disord Drug Targets. 2011 Oct;11(5):466-74. 

  • 6. Wizman S, Lamarre V, Coic L, Kakkar F, Le Meur J-B, Rousseau C, et al. Awareness of cytomegalovirus and risk factors for susceptibility among pregnant women, in Montreal, Canada. BMC Pregnancy Childbirth. 2016 March;16:54. 

  • 7. Binda S, Pellegrinelli L, Terraneo M, Caserini A, Primache V, Bubba L, et al. What people know about congenital CMV: an analysis of a large heterogeneous population through a web-based survey. BMC Infect Dis. 2016 Sep;16(1):513. 

  • 8. Rawlinson WD, Boppana SB, Fowler KB, Kimberlin DW, Lazzarotto T, Alain S, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis. 2017 Jun;17(6):e177-88. 

  • 9. Grinberg A, Katorza E, Hoffman D, Ber R, Mayer A, Lipitz S. Volumetric MRI Study of the Brain in Fetuses with Intrauterine Cytomegalovirus Infection and Its Correlation to Neurodevelopmental Outcome. AJNR Am J Neuroradiol. 2019 Feb;40(2):353-8. 

  • 10. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007;17(5):355-63. 

  • 11. de Vries JJC, Korver AMH, Verkerk PH, Rusman L, Claas ECJ, Loeber JG, et al. Congenital cytomegalovirus infection in The Netherlands: birth prevalence and risk factors. J Med Virol. 2011 Oct;83(10):1777-82. 

  • 12. Mussi-Pinhata MM, Yamamoto AY, Moura Brito RM, de Lima Isaac M, de Carvalho e Oliveira PF, Boppana S, et al. Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clin Infect Dis. 2009 Aug;49(4):522-8. 

  • 13. Yamamoto AY, Mussi-Pinhata MM, Boppana SB, Novak Z, Wagatsuma VM, Oliveira P de F, et al. Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. Am J Obstet Gynecol. 2010 Mar;202(3):297.e1-8. 

  • 14. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007;17(4):253-76. 

  • 15. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med. 2001 May;344(18):1366-71. 

  • 16. Nigro G, Adler SP, La Torre R, Best AM. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med. 2005;353(13):1350-62. 

  • 17. Enders G, Daiminger A, Bader U, Exler S, Enders M. Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol. 2011 Nov;52(3):244-6. 

  • 18. Picone O, Vauloup-Fellous C, Cordier AG, Guitton S, Senat M V, Fuchs F, et al. A series of 238 cytomegalovirus primary infections during pregnancy: description  and outcome. Prenat Diagn. 2013 Aug;33(8):751-8. 

  • 19. Hughes BL, Gyamfi-Bannerman C. Diagnosis and antenatal management of congenital cytomegalovirus infection. Am J Obstet Gynecol. 2016 Jun;214(6):B5-11. 

  • 20. Nigro G, Anceschi MM, Cosmi E V. Clinical manifestations and abnormal laboratory findings in pregnant women with primary cytomegalovirus infection. BJOG. 2003;110(6):572-7. 

  • 21. Pourrat O, Roblot F, Gombert JM, Pierre F. Clinical manifestations and abnormal laboratory findings in pregnant women with primary cytomegalovirus infection. BJOC. 2003;110(1):1139-40. 

  • 22. Revello MG, Gerna G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev. 2002;15(4):680-715. 

  • 23. Forsgren M. Prevention of congenital and perinatal infections. Euro Surveillance. 2009 Mar 5;14(9):2-4. 

  • 24. Saldan A, Forner G, Mengoli C, Gussetti N, Palu G, Abate D. Testing for Cytomegalovirus in Pregnancy. J Clin Microbiol. 2017 Mar;55(3):693-702. 

  • 25. Stagno S, Pass RF, Cloud G, Britt WJ, Henderson RE, Walton PD, et al. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA. 1986 Oct;256(14):1904-8. 

  • 26. Daiminger A, Bader U, Enders G. Pre- and periconceptional primary cytomegalovirus infection: risk of vertical transmission and congenital disease. BJOG. 2005 Feb;112(2):166-72. 

  • 27. Gentile M, Galli C, Pagnotti P, Di Marco P, Tzantzoglou S, Bellomi F, et al. Measurement of the sensitivity of different commercial assays in the diagnosis of CMV infection in pregnancy. Eur J Clin Microbiol Infect Dis. 2009 Aug;28(8):977-81. 

  • 28. Lazzarotto T, Guerra B, Lanari M, Gabrielli L, Landini MP. New advances in the diagnosis of congenital cytomegalovirus infection. J Clin Virol. 2008 Mar;41(3):192-7. 

  • 29. Chou SW, Dennison KM. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J Infect Dis. 1991 Jun;163(6):1229-34. 

  • 30. Arora N, Novak Z, Fowler KB, Boppana SB, Ross SA. Cytomegalovirus viruria and DNAemia in healthy seropositive women. J Infect Dis. 2010 Dec;202(12):1800-3. 

  • 31. Revello MG, Furione M, Rognoni V, Arossa A, Gerna G. Cytomegalovirus DNAemia in pregnant women. J Clin Virol. 2014 Dec;61(4):590-2. 

  • 32. Kim DJ, Kim SJ, Park J, Choi GS, Lee S, Kwon CD, et al. Real-time PCR assay compared with antigenemia assay for detecting cytomegalovirus infection in kidney transplant recipients. Transplant Proc. 2007 Jun;39(5):1458-60. 

  • 33. Seehofer D, Meisel H, Rayes N, Stein A, Langrehr JM, Settmacher U, et al. Prospective evaluation of the clinical utility of different methods for the detection of human cytomegalovirus disease after liver transplantation. Am J Transplant. 2004 Aug;4(8):1331-7. 

  • 34. Ornoy A, Diav-Citrin O. Fetal effects of primary and secondary cytomegalovirus infection in pregnancy. Reprod Toxicol. 2006 May;21(4):399-409. 

  • 35. Benoist G, Salomon LJ, Jacquemard F, Daffos F, Ville Y. The prognostic value of ultrasound abnormalities and biological parameters in blood of fetuses infected with cytomegalovirus. BJOG. 2008 Jun;115(7):823-9. 

  • 36. Lazzarotto T, Guerra B, Gabrielli L, Lanari M, Landini MP. Update on the prevention, diagnosis and management of cytomegalovirus infection during pregnancy. Clin Microbiol Infect. 2011 Sep;17(9):1285-93. 

  • 37. Enders G, Bader U, Lindemann L, Schalasta G, Daiminger A. Prenatal diagnosis of congenital cytomegalovirus infection in 189 pregnancies with known outcome. Prenat Diagn. 2001 May;21(5):362-77. 

  • 38. Gouarin S, Gault E, Vabret A, Cointe D, Rozenberg F, Grangeot-Keros L, et al. Real-time PCR quantification of human cytomegalovirus DNA in amniotic fluid samples from mothers with primary infection. J Clin Microbiol. 2002 May;40(5):1767-72. 

  • 39. Guerra B, Lazzarotto T, Quarta S, Lanari M, Bovicelli L, Nicolosi A, et al. Prenatal diagnosis of symptomatic congenital cytomegalovirus infection. Am J Obstet Gynecol. 2000 Aug;183(2):476-82. 

  • 40. Romanelli RM de C, Magny JF, Jacquemard F. Prognostic markers of symptomatic congenital cytomegalovirus infection. Braz J Infect Dis. 2008 Feb;12(1):38-43. 

  • 41. Goegebuer T, Van Meensel B, Beuselinck K, Cossey V, Van Ranst M, Hanssens M, et al. Clinical predictive value of real-time PCR quantification of human cytomegalovirus DNA in amniotic fluid samples. J Clin Microbiol. 2009 Mar;47(3):660-5. 

  • 42. Diogo MC, Glatter S, Binder J, Kiss H, Prayer D. The MRI spectrum of congenital cytomegalovirus infection. Prenat Diagn. 2020 Jan;40(1):110-24. 

  • 43. Howard J, Hall B, Brennan LE, Arbuckle S, Craig ME, Graf N, et al. Utility of newborn screening cards for detecting CMV infection in cases of stillbirth. J Clin Virol. 2009 Mar;44(3):215-8. 

  • 44. Cheeran MC-J, Lokensgard JR, Schleiss MR. Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin Microbiol Rev. 2009 Jan;22(1):99-126. 

  • 45. Schleiss MR, Permar SR, Plotkin SA. Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection. Clin Vaccine Immunol. 2017 Dec 5;24(12):e00268-17. 

  • 46. Griffiths PD, Bradburn M, Campbell MJ, Cooper CL, Graham R, Jarvis D, et al. Use of MRI in the diagnosis of fetal brain abnormalities in utero (MERIDIAN): a multicentre, prospective cohort study. Lancet (London, England). 2017 Feb;389(10068):538-46. 

  • 47. Picone O, Teissier N, Cordier AG, Vauloup-Fellous C, Adle-Biassette H, Martinovic J, et al. Detailed in utero ultrasound description of 30 cases of congenital cytomegalovirus infection. Prenat Diagn. 2014 Jun;34(6):518-24. 

  • 48. La Torre R, Nigro G, Mazzocco M, Best AM, Adler SP. Placental enlargement in women with primary maternal cytomegalovirus infection is associated with fetal and neonatal disease. Clin Infect Dis. 2006 Oct;43(8):994-1000. 

  • 49. Malinger G, Lev D, Lerman-Sagie T. Imaging of fetal cytomegalovirus infection. Fetal Diagn Ther. 2011;29(2):117-26. 

  • 50. Averill LW, Kandula VVR, Akyol Y, Epelman M. Fetal Brain Magnetic Resonance Imaging Findings In Congenital Cytomegalovirus Infection With Postnatal Imaging Correlation. Semin Ultrasound CT MR. 2015 Dec;36(6):476-86. 

  • 51. Doneda C, Parazzini C, Righini A, Rustico M, Tassis B, Fabbri E, et al. Early cerebral lesions in cytomegalovirus infection: prenatal MR imaging. Radiology. 2010 May;255(2):613-21. 

  • 52. Masini G, Maggio L, Marchi L, Cavalli I, Ledda C, Trotta M, et al. Isolated fetal echogenic bowel in a retrospective cohort: The role of infection screening. Eur J Obstet Gynecol Reprod Biol. 2018 Dec;231:136-41. 

  • 53. Carcopino X, Chaumoitre K, Shojai R, Akkawi R, Panuel M, Boubli L, et al. Foetal magnetic resonance imaging and echogenic bowel. Prenat Diagn. 2007 Mar;27(3):272-8. 

  • 54. Cannie MM, Devlieger R, Leyder M, Claus F, Leus A, De Catte L, et al. Congenital cytomegalovirus infection: contribution and best timing of prenatal MR imaging. Eur Radiol. 2016 Oct;26(10):3760-9. 

  • 55. Glenn OA, Cuneo AA, Barkovich AJ, Hashemi Z, Bartha AI, Xu D. Malformations of cortical development: diagnostic accuracy of fetal MR imaging. Radiology. 2012 Jun;263(3):843-55. 

  • 56. van der Knaap MS, Vermeulen G, Barkhof F, Hart AAM, Loeber JG, Weel JFL. Pattern of white matter abnormalities at MR imaging: use of polymerase chain reaction testing of Guthrie cards to link pattern with congenital cytomegalovirus infection. Radiology. 2004 Feb;230(2):529-36. 

  • 57. White AL, Hedlund GL, Bale JFJ. Congenital cytomegalovirus infection and brain clefting. Pediatr Neurol. 2014 Mar;50(3):218-23. 

  • 58. Hoffmann C, Grossman R, Bokov I, Lipitz S, Biegon A. Effect of cytomegalovirus infection on temporal lobe development in utero: quantitative MRI studies. Eur Neuropsychopharmacol. 2010 Dec;20(12):848-54. 

  • 59. Limperopoulos C, Robertson RL, Sullivan NR, Bassan H, du Plessis AJ. Cerebellar injury in term infants: clinical characteristics, magnetic resonance imaging findings, and outcome. Pediatr Neurol. 2009 Jul;41(1):1-8. 

  • 60. de Vries LS, Gunardi H, Barth PG, Bok LA, Verboon-Maciolek MA, Groenendaal F. The spectrum of cranial ultrasound and magnetic resonance imaging abnormalities in congenital cytomegalovirus infection. Neuropediatrics. 2004 Apr;35(2):113-9. 

  • 61. Gabrielli L, Bonasoni MP, Santini D, Piccirilli G, Chiereghin A, Petrisli E, et al. Congenital cytomegalovirus infection: patterns of fetal brain damage. Clin Microbiol Infect. 2012 Oct;18(10):E419-27. 

  • 62. Leruez-Ville M, Stirnemann J, Sellier Y, Guilleminot T, Dejean A, Magny J-F, et al. Feasibility of predicting the outcome of fetal infection with cytomegalovirus at  the time of prenatal diagnosis. Am J Obstet Gynecol. 2016;215(3):342.e1-9. 

  • 63. Lipitz S, Hoffmann C, Feldman B, Tepperberg-Dikawa M, Schiff E, Weisz B. Value of prenatal ultrasound and magnetic resonance imaging in assessment of congenital primary cytomegalovirus infection. Ultrasound Obstet Gynecol. 2010;36(6):709-17. 

  • 64. Ho M. The history of cytomegalovirus and its diseases. Med Microbiol Immunol. 2008 Jun;197(2):65-73. 

  • 65. Kylat RI, Kelly EN, Ford-Jones EL. Clinical findings and adverse outcome in neonates with symptomatic congenital cytomegalovirus (SCCMV) infection. Eur J Pediatr. 2006 Nov;165(11):773-8. 

  • 66. Halwachs-Baumann G, Genser B, Danda M, Engele H, Rosegger H, Folsch B, et al. Screening and diagnosis of congenital cytomegalovirus infection: a 5-y study. Scand J Infect Dis. 2000;32(2):137-42. 

  • 67. Revello MG, Lazzarotto T, Guerra B, Spinillo A, Ferrazzi E, Kustermann A, et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med. 2014 Apr;370(14):1316-26. 

  • 68. Kimberlin DW, Jester PM, Sanchez PJ, Ahmed A, Arav-Boger R, Michaels MG, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. 

  • N Engl J Med. 2015 Mar;372(10):933-43. 

  • 69. Kimberlin DW, Lin C-Y, Sanchez PJ, Demmler GJ, Dankner W, Shelton M, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003 Jul;143(1):16-25. 

  • 70. Oliver SE, Cloud GA, Sanchez PJ, Demmler GJ, Dankner W, Shelton M, et al. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol. 2009 Dec;46(Suppl 4):S22-6. 

  • 71. ACOG. Practice Bulletin no. 151: Cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. Obstet Gynecol. 2015 Jun;125(6):1510-25.